HUP0401077A2 - Mycoplasma bovis fertőzési modell, valamint eljárások M. bovis bejuttatására és tüdőgyulladásos tüdőléziók indukálására - Google Patents

Mycoplasma bovis fertőzési modell, valamint eljárások M. bovis bejuttatására és tüdőgyulladásos tüdőléziók indukálására

Info

Publication number
HUP0401077A2
HUP0401077A2 HU0401077A HUP0401077A HUP0401077A2 HU P0401077 A2 HUP0401077 A2 HU P0401077A2 HU 0401077 A HU0401077 A HU 0401077A HU P0401077 A HUP0401077 A HU P0401077A HU P0401077 A2 HUP0401077 A2 HU P0401077A2
Authority
HU
Hungary
Prior art keywords
methods
bovis
inducing
administering
lung lesions
Prior art date
Application number
HU0401077A
Other languages
English (en)
Inventor
Robin Lee Keich
László Pál Stipkovits
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0401077A2 publication Critical patent/HUP0401077A2/hu
Publication of HUP0401077A3 publication Critical patent/HUP0401077A3/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/101—Bovine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/30—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)

Abstract

A találmány tárgyát egy állatkísérletes Mycoplasma bovis fertőzésimodell képezi, továbbá eljárások M. bovis bejuttatására és M. bovisáltal állatban okozott betegség vagy rendellenesség indukálására éslétrehozására. A találmány szerinti M. bovis fertőzési modell alkalmaspotenciális vakcinák hatékonyságának kiértékelésére. Ó
HU0401077A 2001-08-28 2002-07-25 Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions HUP0401077A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31532401P 2001-08-28 2001-08-28
PCT/IB2002/003074 WO2003017755A2 (en) 2001-08-28 2002-07-25 Mycoplasma bovis challenge model, methods for administering m.bovis and methods for inducing pneumonic lung lesions

Publications (2)

Publication Number Publication Date
HUP0401077A2 true HUP0401077A2 (hu) 2004-08-30
HUP0401077A3 HUP0401077A3 (en) 2004-10-28

Family

ID=23223885

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401077A HUP0401077A3 (en) 2001-08-28 2002-07-25 Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions

Country Status (15)

Country Link
US (1) US20030180219A1 (hu)
EP (1) EP1420636A2 (hu)
JP (1) JP2005500845A (hu)
KR (1) KR20040031015A (hu)
CN (1) CN1571633A (hu)
AR (1) AR036355A1 (hu)
BR (1) BR0211563A (hu)
CA (1) CA2457514A1 (hu)
HU (1) HUP0401077A3 (hu)
IL (1) IL159145A0 (hu)
MX (1) MXPA04001872A (hu)
PL (1) PL368826A1 (hu)
RU (1) RU2004105962A (hu)
WO (1) WO2003017755A2 (hu)
ZA (1) ZA200309625B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030619A2 (en) * 2006-09-07 2008-03-13 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
AR069087A1 (es) 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
RU2510280C2 (ru) 2008-06-27 2014-03-27 Пфайзер Инк. Новые адъювантные композиции
AU2012258478B2 (en) * 2008-06-27 2013-10-03 Zoetis Services Llc Novel adjuvant compositions
CN102202685A (zh) 2008-10-31 2011-09-28 贝林格尔.英格海姆维特梅迪卡有限公司 包含来自牛枝原体的抗原的多种抗原在多价疫苗组合物中的用途
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
SG11201505089YA (en) 2012-12-28 2015-07-30 Boehringer Ingelheim Vetmed Method of making a mycoplasma vaccine
EP3049105B1 (en) 2013-09-19 2020-12-30 Moredun Research Institute Vaccine
MX2017009306A (es) 2015-01-16 2017-11-08 Zoetis Services Llc Vacuna contra la fiebre aftosa.
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN109833333A (zh) * 2019-02-16 2019-06-04 首都医科大学附属北京中医医院 一种制备肺炎大鼠模型的方法及模型评价方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782508B2 (en) * 1999-11-08 2005-08-04 Biomune Vaccines for mycoplasma bovis and methods of use
WO2003004051A2 (en) * 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle

Also Published As

Publication number Publication date
KR20040031015A (ko) 2004-04-09
EP1420636A2 (en) 2004-05-26
BR0211563A (pt) 2004-07-13
CA2457514A1 (en) 2003-03-06
AR036355A1 (es) 2004-09-01
PL368826A1 (en) 2005-04-04
IL159145A0 (en) 2004-06-01
JP2005500845A (ja) 2005-01-13
CN1571633A (zh) 2005-01-26
WO2003017755A2 (en) 2003-03-06
WO2003017755A3 (en) 2003-10-23
ZA200309625B (en) 2004-12-13
HUP0401077A3 (en) 2004-10-28
RU2004105962A (ru) 2005-03-27
MXPA04001872A (es) 2004-06-15
US20030180219A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
CY1123050T1 (el) Φαρμακα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
CY1118020T1 (el) Τροποποιημενα φθοριομενα αναλογα νουκλεοζιδιων
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
UA81676C2 (ru) Композиция для лечения инфекций у крупного рогатого скота и свиней
BR0311126A (pt) Composições e método para tratar infecção em gado bovino e em suìnos
CY1118179T1 (el) Φαρμακευτικη συνθεση
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
HUP0401077A2 (hu) Mycoplasma bovis fertőzési modell, valamint eljárások M. bovis bejuttatására és tüdőgyulladásos tüdőléziók indukálására
HUP0203056A1 (hu) Vakcinakészítmény
ATE426412T1 (de) Adjuvante influenza-vakzine
CY1117290T1 (el) Εμβολιο φυματιωσης και μεθοδος χρησης αυτου
ATE452900T1 (de) Impfstoff gegen das west-nile-virus
HUP0301634A2 (hu) Hőmérséklet-érzékeny, élő vakcina Mycoplasma hyopneumoniaera
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
TR201820975A2 (tr) İbuprofen, Psödoefedrin ve Erdostein İçeren Uzatılmış Salım Sağlayan Farmasötik Kompozisyon
DE602004023196D1 (de) Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird)
ATE359815T1 (de) Streptococcus-phocae-vakzine
ATE544856T1 (de) Peptid- und nukleotidsequenzen von anisakis spp. und ihre verwendung
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
EP1578353A4 (en) METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTION DISEASES
ATE467424T1 (de) Escape-mutanten des newcastle-disease-virus als marker-vakzine
DK1660121T3 (da) Levende svækket bakteriel vaccine
ATE373675T1 (de) Impfstoff gegen pferdearteritisvirus